We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
Key Takeaways
The Cooper Companies is set to report fiscal Q3 2026 results, with sales and EPS estimates implying growth.
COO's CooperVision unit is expected to benefit from MyDay demand, Biofinity lenses and myopia control growth.
COO may gain from improving fertility trends and cost efficiencies, while Asia Pacific remains a key headwind.
The Cooper Companies (COO - Free Report) is scheduled to report third-quarter fiscal 2026 results on Sept. 9, after market close.
The Zacks Consensus Estimate for sales is pegged at $1.1 billion, implying 3.6% year-over-year growth. The consensus estimate for the bottom line is pinned at $1.11 per share, suggesting growth of 0.9%.
The earnings per share (EPS) estimates have remained stable over the past seven days.
Earnings Surprise History
The company delivered an earnings surprise of 10% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.8%.
What the Zacks Model Unveils for COO
Our proven model does not conclusively predict an earnings beat for The Cooper Companies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
COO’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank of COO: The company carries a Zacks Rank #4 (Sell) at present.
The Cooper Companies’ fiscal third-quarter performance is expected to have benefited from continued strength in its CooperVision business, improving fertility trends within CooperSurgical and ongoing operational efficiency initiatives. Management maintained its fiscal 2026 adjusted EPS guidance of $4.58-$4.66 after a strong fiscal second quarter, reflecting confidence in execution despite macroeconomic headwinds in Asia Pacific.
CooperVision is likely to have remained the company's primary growth driver during the to-be-reported quarter. Revenue growth is expected to have been supported by healthy demand in the Americas and EMEA, where premium daily silicone hydrogel lenses, particularly the MyDay portfolio, continued gaining traction through expanding customer partnerships and branded contract wins. Biofinity toric and multifocal lenses are also expected to have contributed meaningfully, while MyDay multifocal and Energys likely sustained strong adoption, supported by their premium positioning and broader rollout across markets.
Myopia control products are expected to have remained a meaningful growth contributor. MiSight delivered 24% growth in the prior quarter, driven by strong momentum in Japan, encouraging adoption of MyDay MiSight in Europe and expanding consumer awareness campaigns during the back-to-school season. Management indicated that clinician reception remained favorable and investments in additional product launches should continue supporting long-term growth, even as increasing adoption of spectacle-based myopia control products creates some near-term competitive pressure.
Within CooperSurgical, fertility trends are expected to have remained favorable as IVF market conditions continued improving across key markets. Management expects the fertility business to return to mid-single-digit growth during the second half after a stronger-than-expected prior quarter that benefited from capital equipment sales and temporary distributor restocking in the Middle East. Continued demand for genomics, consumables and Witness laboratory tracking systems, along with new clinic wins and expansion within existing accounts, is expected to have supported quarterly performance.
Regionally, the Americas and EMEA are expected to have maintained healthy growth trajectories, but Asia Pacific is likely to have remained a meaningful headwind. Management had guided for another quarterly decline in the region due to persistent consumer weakness in Japan and China, continued rationalization of legacy hydrogel products and rising e-commerce activity, where The Cooper Companies has relatively lower exposure.
On the profitability front, restructuring benefits, disciplined cost management and technology-driven efficiency initiatives are expected to have continued supporting operating leverage during the-to-be-reported quarter. While management projected fiscal third-quarter gross margin pressure from unfavorable foreign exchange, tariffs, freight costs and lower production tied to AI-enabled inventory optimization, the company's back-office consolidation efforts, particularly within CooperSurgical, are expected to have helped offset some of these pressures and support earnings performance.
COO’s Share Price Performance
Shares of COO have lost 17.4% in the year-to-date period against the industry’s 7.3% growth. However, the S&P 500 Index has increased 12.2% in the same time frame.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
Key Takeaways
The Cooper Companies (COO - Free Report) is scheduled to report third-quarter fiscal 2026 results on Sept. 9, after market close.
The Zacks Consensus Estimate for sales is pegged at $1.1 billion, implying 3.6% year-over-year growth. The consensus estimate for the bottom line is pinned at $1.11 per share, suggesting growth of 0.9%.
The earnings per share (EPS) estimates have remained stable over the past seven days.
Earnings Surprise History
The company delivered an earnings surprise of 10% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.8%.
What the Zacks Model Unveils for COO
Our proven model does not conclusively predict an earnings beat for The Cooper Companies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
COO’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank of COO: The company carries a Zacks Rank #4 (Sell) at present.
The Cooper Companies, Inc. Price and EPS Surprise
The Cooper Companies, Inc. price-eps-surprise | The Cooper Companies, Inc. Quote
Factors Likely to Drive COO’s Q3 Performance
The Cooper Companies’ fiscal third-quarter performance is expected to have benefited from continued strength in its CooperVision business, improving fertility trends within CooperSurgical and ongoing operational efficiency initiatives. Management maintained its fiscal 2026 adjusted EPS guidance of $4.58-$4.66 after a strong fiscal second quarter, reflecting confidence in execution despite macroeconomic headwinds in Asia Pacific.
CooperVision is likely to have remained the company's primary growth driver during the to-be-reported quarter. Revenue growth is expected to have been supported by healthy demand in the Americas and EMEA, where premium daily silicone hydrogel lenses, particularly the MyDay portfolio, continued gaining traction through expanding customer partnerships and branded contract wins. Biofinity toric and multifocal lenses are also expected to have contributed meaningfully, while MyDay multifocal and Energys likely sustained strong adoption, supported by their premium positioning and broader rollout across markets.
Myopia control products are expected to have remained a meaningful growth contributor. MiSight delivered 24% growth in the prior quarter, driven by strong momentum in Japan, encouraging adoption of MyDay MiSight in Europe and expanding consumer awareness campaigns during the back-to-school season. Management indicated that clinician reception remained favorable and investments in additional product launches should continue supporting long-term growth, even as increasing adoption of spectacle-based myopia control products creates some near-term competitive pressure.
Within CooperSurgical, fertility trends are expected to have remained favorable as IVF market conditions continued improving across key markets. Management expects the fertility business to return to mid-single-digit growth during the second half after a stronger-than-expected prior quarter that benefited from capital equipment sales and temporary distributor restocking in the Middle East. Continued demand for genomics, consumables and Witness laboratory tracking systems, along with new clinic wins and expansion within existing accounts, is expected to have supported quarterly performance.
Regionally, the Americas and EMEA are expected to have maintained healthy growth trajectories, but Asia Pacific is likely to have remained a meaningful headwind. Management had guided for another quarterly decline in the region due to persistent consumer weakness in Japan and China, continued rationalization of legacy hydrogel products and rising e-commerce activity, where The Cooper Companies has relatively lower exposure.
On the profitability front, restructuring benefits, disciplined cost management and technology-driven efficiency initiatives are expected to have continued supporting operating leverage during the-to-be-reported quarter. While management projected fiscal third-quarter gross margin pressure from unfavorable foreign exchange, tariffs, freight costs and lower production tied to AI-enabled inventory optimization, the company's back-office consolidation efforts, particularly within CooperSurgical, are expected to have helped offset some of these pressures and support earnings performance.
COO’s Share Price Performance
Shares of COO have lost 17.4% in the year-to-date period against the industry’s 7.3% growth. However, the S&P 500 Index has increased 12.2% in the same time frame.
Image Source: Zacks Investment Research
Stocks Worth a Look
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.